葡萄糖皮质醇诱导的骨质疏松症 (GIOP)
S S Jha1,2,3,4
1Harishchandra Institute of Orthopaedics and Research, Patna, India.
Indian journal of orthopaedics
|December 18, 2023
概括
葡萄糖皮质醇的使用正在增加,增加骨质疏松症和骨折的风险. 谨慎管理和像双酸盐这样的治疗方法对于防止这些不良影响至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 由于快速的好处,葡萄糖皮质体的使用在风湿和呼吸系统疾病中越来越多.
- 这种广泛使用与骨质疏松症和脆弱性骨折的增加有关.
- 谨慎的葡萄糖皮质激素管理需要注意剂量,途径和支持因素.
研究的目的:
- 为了突出葡萄糖皮质醇诱导的骨质疏松症和脆弱性骨折的风险.
- 强调在临床实践中需要谨慎的管理策略.
- 讨论治疗干预措施,以预防葡萄糖皮质类药物治疗患者的骨折.
主要方法:
- 关于使用葡萄糖皮质体和骨健康的当前文献的综述.
- 对世卫组织骨质疏松症风险分层指南的分析.
- 讨论药理干预措施,包括双酸盐,特里巴酸盐和德诺苏马布.
主要成果:
- 葡萄糖皮质类药物显著增加骨质疏松症和随后的脆弱性骨折的风险.
- 有效的预防策略包括优化葡萄糖皮质激素治疗和实施骨保护措施.
- 治疗选择,如双酸盐,特里巴拉提德,和denosumab对于管理骨折风险至关重要.
结论:
- 优化葡萄糖皮质醇治疗和了解其不良影响是必不可少的.
- 用骨保护剂进行主动管理是必要的,以减轻骨折风险.
- 对葡萄糖皮质醇代谢和量身定制的治疗策略进行进一步研究是有必要的.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Glucagon-like Receptor Agonists
327
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
327
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Hypoglycemia and Glucagon
266
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
266
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
266
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
266


